help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on October 25, 2005
Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2005-1349
A more recent version of this article appeared on January 1, 2006
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
91/1/204    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by HOFFMANN, K. M.
Right arrow Articles by JENSEN, R. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by HOFFMANN, K. M.
Right arrow Articles by JENSEN, R. T.

Submitted on June 16, 2005
Accepted on October 18, 2005

Patients with MEN1 with Gastrinomas Have an Increased Risk of Severe Esophageal Disease Including Stricture, and the Premalignant Condition, Barrett's Esophagus

K. MARTIN HOFFMANN, FATHIA GIBRIL, LAURENCE K. ENTSUAH, JOSE SERRANO, and ROBERT T. JENSEN*

Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892-1804

* To whom correspondence should be addressed. E-mail: robertj{at}bdg10.niddk.nih.gov.

Context: MEN1 patients frequently develop Zollinger-Ellision syndrome (MEN1/ZES). Although esophageal reflux symptoms are common in these patients, little is known about long-term occurrence of severe peptic esophageal disease including strictures and Barrett's esophagus (BE).

Objective: To prospectively analyze the frequency of severe peptic esophageal disease in ZES patients with/without MEN1.

Setting: Tertiary care research-center.

Patients: 295 patients (80 = MEN1/ZES, 215 = sporadic ZES) participating in a prospective study.

Interventions-outcome measures: Assessment of MEN1, acid hypersecretion, UGI endoscopy/biopses and tumor status initially and at each follow-up. Esophageal manometry was performed in 89 patients. Frequency/type of esophageal disease was correlated with clinical/laboratory/tumoral features of ZES/MEN1.

Results: In MEN1/ZES patients esophageal stricture was 3-fold higher, BE 5-fold higher, dysplasia 8-fold higher and one patient died of esophageal adenocarcinoma. Esophageal symptoms were more frequent/severe in MEN1/ZES, but known risk factors for severe esophageal disease and ZES specific features did not differ between MEN1/ZES and sporadic ZES. In MEN1/ZES the onset of ZES was 10 yr earlier, H2-antagonists were used longer and at lower doses. MEN1/ZES patients with esophageal disease differed from those without in that ZES diagnosis was delayed longer, esophageal symptoms were more frequent/severe, hiatal hernias were more frequent, esophagitis/pyloric scarring were more common, BAO was higher and hyperparathyroidism was underdiagnosed.

Conclusions: This study shows MEN1/ZES patients have a higher incidence of severe esophageal disease including the premalignant condition BE and identifies factors important for their pathogenesis that need to be incorporated into their long-term treatment.


Key words: Zollinger-Ellison syndrome • MEN1 • acid secretion • Barrett's esophagus • gastroesophageal reflux disease • esophageal cancer







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2005 by The Endocrine Society